2,354 material Form 8-K filings that 2,004 companies we cover made with the SEC in November 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). 1,081 of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Director Rodney A. Ferguson resigned from Launch One Acquisition Corp.'s board and its audit and compensation committees, effective immediately. The resignation leaves the audit committee with two members and the board without a majority of independent directors, so the company is out of compliance with two Nasdaq listing rules. The company says it intends to use Nasdaq cure periods and to appoint a new independent director, but no replacement had been named as of the report date.
Ferguson notified the company of his resignation on November 4, 2026, and said it was not due to any disagreement with the company.
The audit committee now has two members, Mr. Atwood and Mr. Rogers, below Nasdaq's three-member requirement; Nasdaq notified the company of this on December 6, 2026, a date later than the report's November 9, 2026 filing date.
Nasdaq notified the company on November 6, 2026 that the board no longer has a majority of independent directors.
No replacement director has been appointed, and the filing gives no assurance on timing.
Larimar Therapeutics said it completed its rolling Biologics License Application with the FDA, seeking accelerated approval of nomlabofusp for Friedreich's ataxia. The company also disclosed a preliminary, unaudited $128.7 million in cash, cash equivalents and marketable securities as of September 30, 2026, with its quarter-end close not yet complete, so shareholders should note that figure could change.
Rolling BLA submission to the FDA completed; the company seeks accelerated approval based on skin frataxin as a potential novel surrogate endpoint.
Preliminary cash, cash equivalents and marketable securities of approximately $128.7 million as of September 30, 2026, subject to change after financial statement closing procedures.
The updated corporate deck projects cash runway into late Q2 2027 and lists BLA acceptance for early 2027 and U.S. approval for mid-2027 as estimated timing.
Aldeyra asked the FDA's Division of Ophthalmology to request that review of the ADX-2191 IND for primary vitreoretinal lymphoma move to the Division of Hematologic Malignancies 2, and it withdrew the Special Protocol Assessment for the planned trial. The company said the regulatory path is now uncertain and may be significantly delayed, and that the planned trial will need to be redesigned, which could raise costs and shorten its cash runway.
Aldeyra requested a review jurisdiction transfer to the FDA's Division of Hematologic Malignancies 2 (DHM2), announced November 9, 2026
The company withdrew the SPA protocol for ADX-2191 in PVRL, which the Division of Ophthalmology had previously agreed to
Aldeyra does not expect to start the planned trial while the request is pending; the FDA may deny the request or transfer the IND to another division
The filing warns of higher costs, a shorter cash runway and possible need for earlier capital raising
TMC USA, a subsidiary of TMC the metals Co Inc., received a letter from NOAA stating it expects to notify TMC USA of its final determination on certification of its consolidated application for an exploration license and commercial recovery permit by mid-December 2026. The filing notes the timing is an estimate, DSHMRA sets no mandatory deadline, and certification is an intermediate step that is not an approval or issuance of a license or permit.
NOAA letter received by TMC USA on November 3, 2026
NOAA expects to notify TMC USA of its final determination on certification by mid-December 2026
Application covers an exploration license and a commercial recovery permit under DSHMRA
Filing states certification does not constitute approval or issuance of a license or permit
Vistagen reported constructive FDA feedback from a Type C meeting on registrational paths for its lead product candidate, fasedienol, in social anxiety disorder. The company plans to use interim assessments, submit a revised protocol, and focus development on the general SAD population rather than acute treatment alone.
FDA gave constructive feedback on using the Liebowitz Social Anxiety Scale as the primary endpoint in a future Phase 3 study.
Vistagen plans to add interim assessments using eDiaries and qualitative patient surveys and to submit a revised protocol to the FDA.
The company plans to pursue fasedienol for overall, not only acute, treatment of SAD, and cited the FDA's recognition of its reported safety profile.
The filing contains no financial results, and the company states that future FDA feedback may not lead to a successful registrational pathway.
Future Vision II Acquisition Corp. (FVN) received written notice on November 5, 2026, from Nasdaq confirming it has regained compliance with the minimum public holders requirement for continued listing on the Nasdaq Capital Market. Nasdaq said the matter is now closed, so the company is no longer under this listing deficiency.
Notice received November 5, 2026 from Nasdaq's Listing Qualifications Department
Compliance regained with minimum public holders requirement under Nasdaq Listing Rule 5550(a)(3)
Nasdaq stated the matter is closed; the 8-K was signed by CEO and Director Danhua Xu on November 9, 2026
Netcapital received a Nasdaq letter on November 5, 2026 granting it an exception to regain compliance with the periodic filing rule, after it missed deadlines for its annual report for the fiscal year ended April 30, 2026 and its quarterly report for the quarter ended July 31, 2026. The company must file both reports by February 9, 2027, or Nasdaq will issue a delisting notice, which the company could appeal to a Nasdaq Hearings Panel. The letter has no immediate effect on trading, but the company says there can be no assurance it will meet the deadline.
Nasdaq Staff letter dated November 5, 2026 grants an exception under Listing Rule 5250(c)(1).
Delinquent Form 10-K (fiscal year ended April 30, 2026) and Form 10-Q (quarter ended July 31, 2026) must be filed on or before February 9, 2027.
If the deadline is missed, Nasdaq will provide written notice of delisting, and the company may appeal to a Nasdaq Hearings Panel.
The letter has no immediate effect on the listing or trading of the common stock.
Novocure said it received a Not Approvable Letter from the U.S. Food and Drug Administration for its Premarket Approval application for Optune Mya, which treats adult patients with brain metastases from non-small cell lung cancer after stereotactic radiation. The FDA said uncertainty about the degree of clinical benefit prevented approval, and the company said it has no assurance that further discussions or submissions will lead to approval.
The FDA's Not Approvable Letter cites uncertainty around the degree of clinical benefit provided by Optune Mya.
The FDA did not raise concerns about the device's safety profile.
Novocure plans to meet with the FDA to see whether any options could support approval without additional clinical studies.
The filing gives no timeline for those discussions and no assurance of approval.
Knightscope received a Nasdaq deficiency letter on November 4, 2026, because its Class A Common Stock closed below the $1.00 minimum bid price for 30 consecutive business days. The company has until May 3, 2027 to regain compliance, and the notice has no immediate effect on its listing, which continues under the symbol KSCP.
Nasdaq deficiency letter received November 4, 2026 for closing below $1.00 minimum bid price for 30 consecutive business days
Compliance Date is May 3, 2027, a 180 calendar day compliance period
Regaining compliance requires closing at $1.00 or more for at least ten consecutive business days
If not compliant, the company may qualify for a second 180 calendar day period, possibly through a reverse stock split; otherwise delisting proceedings could begin, with a right to appeal to a Nasdaq Hearings Panel
Curis received a Nasdaq letter on November 2, 2026 stating its stock closed below the $1.00 minimum bid price for 30 consecutive business days, and it is not eligible for a standard compliance period because of its recent reverse stock split. The company intends to request a new hearing, which would stay further delisting actions, but says there is no assurance the appeal will succeed or that its shares will remain listed on Nasdaq.
Nasdaq letter dated November 2, 2026 cites bid price below $1.00 for 30 consecutive business days under Rule 5550(a)(2)
Company effected a 1-for-20 reverse stock split on July 6, 2026, which makes it ineligible for a compliance period
Following a Nasdaq Hearings Panel decision dated July 24, 2026, Curis is subject to a Discretionary Panel Monitor for one year
Company intends to request a new hearing; no assurance of success or continued Nasdaq listing
On November 5, 2026, the Public Service Commission of Wisconsin approved rate changes in rate cases filed in April 2026 by Wisconsin Electric Power Company, Wisconsin Gas LLC and Wisconsin Public Service Corporation. The presentation slides attached to the filing list an authorized return on equity of 9.50% and an equity ratio of 53.0%, and say a final written order is expected before year-end.
PSCW approved rate changes on November 5, 2026 for Wisconsin Electric, Wisconsin Gas and Wisconsin Public Service
Authorized return on equity of 9.50% and equity ratio of 53.0%
Earnings sharing: no sharing on the first 15 basis points above the allowed ROE, 50/50 on the next 25 basis points, and 100% to customers beyond 40 basis points
Nasdaq granted Fifth Era Acquisition Corp I (FERA) an extension to show its Class A Ordinary Shares have at least 400 Total Holders, the minimum for continued listing on the Nasdaq Global Market. If the company does not meet the terms, Nasdaq will issue a delisting notice, and the company may then appeal to a Listing Qualifications Panel, so the listing remains at risk.
Nasdaq notice dated September 14, 2026 cited non-compliance with Listing Rule 5450(a)(2), which requires at least 400 Total Holders
Company submitted its compliance plan to Nasdaq on October 28, 2026
Nasdaq granted an extension on November 5, 2026; documentation is due on or before March 15, 2027
Barfresh Food Group received a Nasdaq letter on November 5, 2026 saying its common stock closed below $1.00 for 30 consecutive business days. The company has until May 4, 2027 to regain compliance, and it also faces a separate market value requirement deadline of February 1, 2027. The notice does not change current trading, but a failure to cure could lead to delisting risk for shareholders.
Nasdaq notice received November 5, 2026 for failing the $1.00 minimum closing bid price for 30 consecutive business days
Compliance requires at least $1.00 closing bid for 10 consecutive business days by May 4, 2027, with a possible extension
Company must meet MVLS of $35,000,000 by February 1, 2027; a reverse split must be completed no later than ten business days before May 4, 2027
Common stock continues to trade on The Nasdaq Capital Market under the symbol BRFH
BioCardia said it finished its clinical consultation with Japan's PMDA on application materials for the CardiAMP Cell Therapy System for ischemic heart failure, a step toward submitting a marketing approval application. The company states that completing consultations does not constitute regulatory approval, and the product remains subject to PMDA review.
Consultation with Japan's PMDA on application materials completed, announced November 6, 2026
CardiAMP is intended for ischemic heart failure; CEO Peter Altman targets first patient treatments in Japan and commercial revenues in 2028
Completion does not equal regulatory approval; product remains subject to PMDA review
Pantages Capital Acquisition Corporation received a Nasdaq extension to regain compliance with the minimum 400 Total Holders requirement for its Class A ordinary shares. The company must file proof of at least 400 Total Holders by March 1, 2027, or Nasdaq will provide notice that its securities will be delisted, with a right to appeal to a Listing Qualifications Panel.
Nasdaq notice of non-compliance with Listing Rule 5450(a)(2) was received September 2, 2026
Company submitted its compliance plan to Nasdaq on October 16, 2026
Nasdaq granted an extension on October 27, 2026; deadline to file holder documentation is March 1, 2027
If requirement is not met, Nasdaq will issue a delisting notice; the company may appeal to a Listing Qualifications Panel
Essential Utilities disclosed that American Water, Essential Utilities and their affiliates filed a Stipulation of Settlement with the New Jersey Board of Public Utilities (NJBPU) on November 2, 2026, in the proceeding to approve the proposed merger. The stipulation was entered into with all parties, including NJBPU staff and the New Jersey Division of Rate Counsel, and is subject to review and approval by the NJBPU. The filing shows progress on regulatory approval, but the merger still requires the NJBPU's approval before it can proceed.
Stipulation of Settlement filed November 2, 2026, with all parties in the NJBPU proceeding
Stipulation posted to the NJBPU website as of November 5, 2026, and remains subject to NJBPU review and approval
Merger agreement with American Water was signed October 26, 2025; Essential Utilities would become a wholly owned subsidiary
Myriad Genetics said it detected unauthorized access to its IT network on November 2, 2026, and temporarily suspended testing operations and order management systems while it investigates. The company said most systems have returned to normal, that it is still assessing whether any patient records were accessed, and that it does not believe the incident will have a material adverse effect on its business.
Unauthorized access detected on November 2, 2026, within the company's IT network environment
Testing operations and order management systems were temporarily suspended; most systems have since returned to normal operations
Whether patient records were accessed is still under investigation; external experts have been engaged
Company states it does not believe the incident will have a material adverse effect on its business
Local Bounti received a notice on November 4, 2026, that the NYSE accepted its request to extend the deadline to regain compliance with the minimum market capitalization standard from November 5, 2026 to August 5, 2027. The company must reach an average global market capitalization of at least $50 million or stockholders' equity of at least $50 million by then, and the NYSE could start delisting proceedings if progress is insufficient, so shareholders face continued listing risk.
NYSE accepted the company's October 20, 2026 request for a nine-month extension.
The compliance deadline moves from November 5, 2026 to August 5, 2027, the maximum 18-month period under NYSE rules.
To regain compliance, the company needs average global market capitalization of at least $50 million over 30 trading days, or stockholders' equity of at least $50 million.
Common stock remains listed on the NYSE during the cure period, subject to quarterly NYSE reviews of progress.
Karyopharm Therapeutics filed for Chapter 11 bankruptcy protection on November 2, 2026, and Nasdaq notified the company on November 4 that its common stock will be delisted. The company will not appeal, and the stock is expected to move to an over-the-counter market under the symbol KPTIQ. The filing says the proposed reorganization plan gives common stock and Series A preferred holders no payment, so existing equity is expected to have no value.
Nasdaq trading in common stock suspends at the opening of business on November 11, 2026.
Common stock expected to trade over the counter under the symbol KPTIQ on or after November 11, 2026.
Joint prepackaged Chapter 11 plan filed November 2, 2026 provides no distribution to common or 0% Series A Convertible Perpetual Preferred Stock holders.
The company expects existing equity securities to have no value and holders to face a complete loss.
Cognition Therapeutics received a Nasdaq deficiency letter on November 3, 2026, because its common stock has closed below the $1.00 minimum bid price for 30 consecutive business days. The company has until May 3, 2027, to regain compliance, and the letter has no immediate effect on its listing. Third-quarter results showed a smaller net loss than a year earlier, but the company reported $31.5 million in cash as of September 30, 2026.
Nasdaq letter dated November 3, 2026 cites a closing bid price below $1.00 for 30 consecutive business days; compliance deadline is May 3, 2027
Q3 2026 net loss was $4.1 million, or $(0.04) per share, versus $4.9 million, or $(0.06) per share, in Q3 2025
Research and development expenses rose to $5.1 million from $3.8 million, while general and administrative expenses fell to $2.3 million from $2.6 million
Cash and restricted cash equivalents were $31.5 million at September 30, 2026; the company estimates funding into the fourth quarter of 2027
Intrusion Inc. received a Nasdaq notice granting it a second 180-day period, until May 3, 2027, to regain compliance with the $1.00 minimum bid price requirement after missing the initial deadline of November 3, 2026. The stock continues to trade on the Nasdaq Capital Market under INTZ, but if the company does not regain compliance, Nasdaq will move toward delisting, and the company may need a reverse stock split.
Nasdaq granted an additional 180 calendar days, until May 3, 2027, to regain the $1.00 minimum bid price requirement.
The company did not regain compliance during the initial 180-day period, which expired November 3, 2026.
To regain compliance, the closing bid price must be at least $1.00 for 10 consecutive business days before May 3, 2027, and any reverse stock split must be completed no later than ten business days before that date.
The company makes no assurance it will regain compliance or successfully appeal any future delisting determination.
Bio Green Med Solution, Inc. filed a Form 8-K dated November 4, 2026, that lists Item 3.01 (Delisting or Listing Rule Notice) and Item 9.01 (Financial Statements and Exhibits). The text provided includes only the Item 9.01 exhibit list and signature block, so the specific exchange, rule, and deadline are not stated in the material reviewed. Because the item concerns a listing notice, shareholders should review the full filing for its terms.
Exhibit 104 is the Cover Page Interactive Data File; the text provided does not state the exchange or compliance deadline
Signed by Datuk Dr. Doris Wong Sing Ee, Chief Executive Officer and Executive Director
Nasdaq has started procedures to delist Cayson Acquisition Corp's securities after the company did not show it met the Minimum Total Holders Rule by its extended October 26, 2026 deadline. The company has appealed the determination to keep its listing and says it expects to provide documentation that could make the matter moot before an appeal hearing is scheduled.
Nasdaq Listing Rule 5450(a)(2) requires at least 400 Total Holders, counting beneficial holders and holders of record.
Nasdaq extended the compliance deadline to October 26, 2026, but the company did not evidence compliance within that period.
Nasdaq notified the company on October 29, 2026 that it has initiated delisting procedures.
The company has appealed, and its appeal right ran through November 5, 2026.
Peapack Private Bank & Trust filed a complaint in New York State Supreme Court, Queens County, demanding repayment of all amounts outstanding under Fly-E Group's revolving credit facility. The lender seeks at least $3.9 million in principal plus interest, fees and possession of the collateral securing the debt, which could weigh on the company's finances and operations.
Complaint filed October 30, 2026, against the company, two subsidiaries as co-borrowers, corporate guarantors and two individual guarantors, including CEO Zhou Ou
Lender seeks at least $3.9 million in outstanding principal, plus accrued interest at a post-forbearance rate of 15.375% per annum, default interest, late charges and attorneys' fees
Credit facility matured August 31, 2025; forbearance agreement, amended May 28, 2026, ran through June 30, 2026; lender demanded collateral on October 20, 2026
The company said it is reviewing the complaint and evaluating its defenses and other available responses
Polar Power received written confirmation from Nasdaq that it complies with the $2.5 million minimum stockholders' equity requirement. The company also announced Phase 2 of its restructuring, which targets further facility consolidation and lower fixed overhead, and it is evaluating refinancing and other capital-raising options. Nasdaq said the company must keep showing compliance in its next periodic report or it may face delisting proceedings.
Nasdaq staff determined Polar complies with the $2.5 million minimum stockholders' equity requirement, based on its Form 8-K dated October 23, 2026
Phase 1 of the restructuring delivered about $1.03 million in annualized cost reductions; the target is about $2 million in total annualized savings, including Phase 1
Polar is evaluating refinancing and other capital-raising alternatives, and Nasdaq cautioned that delisting proceedings may follow if compliance is not evidenced in the next periodic report
3M agreed on November 3, 2026 to a settlement intended to resolve most PFAS-related personal injury claims in the AFFF multidistrict litigation. The company will contribute a nominal $7.35 billion from 2026 through 2034, with a present value of $5.8 billion, and will record that amount as a pre-tax charge in the fourth quarter of 2026. The company says the charge does not change its previously issued 2026 guidance, and payments depend on claimant participation thresholds.
Nominal commitment of $7.35 billion over 2026 to 2034; present value of $5.8 billion
Pre-tax charge of $5.8 billion in Q4 2026, treated as a special item in adjusted results; 3M says 2026 guidance is unchanged
$50 million payment due in 2026 and no payments in 2027; payments subject to claimant participation thresholds
Settlement covers about 99% of current personal injury claims, involving roughly 115,000 to 120,000 eligible plaintiffs; 3M does not admit liability
SeaStar Medical announced that the FDA's Center for Biologics Evaluation and Research determined the QUELIMMUNE Pediatric SAVE Surveillance Registry has fulfilled the post-approval study requirements of the original Humanitarian Device Exemption approval. The company says the decision lets hospitals use QUELIMMUNE without the research infrastructure the registry required, which could expand access for critically ill children with sepsis-associated acute kidney injury. The filing gives no revenue, earnings, or financial figures.
FDA's CBER determined the SAVE Registry met post-approval study requirements, announced November 3, 2026
Registry results showed 90-day survival of 65.1% for QUELIMMUNE patients (N=43) versus 47.5% for comparison patients (N=196), P = 0.043
SeaStar says hospitals may now use QUELIMMUNE without registry research infrastructure; the company will continue voluntary enrollment
Driven Brands said its Audit Committee found material fixed asset accounting errors in prior financial statements, including fiscal 2023 through 2025 and the first two 2026 quarterly reports, which must be restated and should not be relied upon. The company delayed its third quarter earnings call and will miss the November 5, 2026 deadline for its third quarter Form 10-Q, and it lowered its 2026 Adjusted EBITDA and Adjusted Diluted EPS outlook.
Audit Committee concluded prior financial statements for fiscal years 2023 to 2025 and the 2026 quarterly reports should not be relied upon; errors primarily involve fixed assets.
Third quarter 2026 Form 10-Q will not be filed by the November 5, 2026 due date; share repurchases are temporarily halted until the company is current on reporting.
2026 Adjusted EBITDA outlook cut to $410 million to $430 million from $430 million to $460 million; Adjusted Diluted EPS cut to $1.10 to $1.20 from $1.15 to $1.25.
Restatement-related costs expected to be at least $50 million in 2026; preliminary third quarter same store sales rose 2.0% for Driven Brands and 4.9% for Take 5.
Ribbon Acquisition Corp. received a Nasdaq notice on October 30, 2026, saying its market value of listed securities has been below the $35 million minimum for 30 consecutive business days. The company has until April 28, 2027 to regain compliance, and its RIBB shares continue to trade on the Nasdaq Capital Market for now, but failing to regain compliance could lead to delisting.
Nasdaq notice dated October 30, 2026; MVLS below $35,000,000 from September 18, 2026 through October 29, 2026
Compliance deadline is April 28, 2027; MVLS must close at $35,000,000 or more for at least 10 consecutive business days
Company does not meet Nasdaq's alternative stockholders' equity or net income requirements
Shares continue to trade under RIBB; the company says it will monitor MVLS and evaluate options
Spire Missouri filed a general rate case with the Missouri Public Service Commission on November 2, 2026, requesting a total revenue requirement increase of $228 million. The filing is based on an average fiscal 2028 future test year rate base of $5.1 billion, and the commission has 11 months to review it, with new rates expected by October 2027. For shareholders, the outcome will determine how much of the utility's infrastructure investment is recovered through customer rates.
Total requested revenue increase of $228 million, including $57 million through the Infrastructure System Replacement Surcharge and $171 million in net new revenues
Proposed rates are based on an average fiscal 2028 future test year rate base of $5.1 billion, assuming a 55.0% common equity ratio and 10.5% return on equity
Company estimates the average residential bill would rise about $10 per month (11%) in western Missouri and about $13 per month (15%) in eastern Missouri if approved as filed
Missouri Public Service Commission has 11 months to consider the filing; new rates expected to be effective by October 2027
Our Bond, Inc. (OBAI) said on November 2, 2026, that Nasdaq notified it that it had regained compliance with the minimum bid price requirement. The company had received a deficiency notice on July 14, 2026, and compliance was restored because its closing bid price stayed above $1.00 for ten consecutive business days. The filing shows the listing issue is resolved but does not disclose financial results or other business developments.
Nasdaq notified the company of a bid price deficiency on July 14, 2026, under Listing Rule 5450(a)(1).
On November 2, 2026, Nasdaq confirmed the company regained compliance.
Compliance was based on a closing bid price above $1.00 for ten consecutive business days.
Nasdaq's Staff issued a Staff Delisting Determination after House of Doge's stock closed at $0.10 or less for ten consecutive trading days, and trading in the common stock will be suspended at the open on November 3, 2026. The company is evaluating whether to request a hearing before a Nasdaq Hearings Panel, and a timely request will not stay the suspension. For shareholders, the suspension could reduce liquidity and the stock price and may limit the company's ability to raise equity capital.
Trading suspension begins at the opening of business on November 3, 2026, with a Form 25-NSE to be filed with the SEC to remove the securities from Nasdaq.
A hearing request and a non-refundable $20,000 fee must reach Nasdaq by 4:00 p.m. Eastern Time on November 3, 2026.
The Staff Delisting Determination is dated October 27, 2026, based on a closing bid price of $0.10 or less from October 13 through October 26, 2026.
The company had been given until March 8, 2027 to regain the $1.00 minimum bid price and has not regained compliance; it expects to file a proxy for a reverse stock split proposal.
NRx Pharmaceuticals said the FDA approved its Abbreviated New Drug Application for Preservative-Free Ketamine ahead of the November 10, 2026 GDUFA goal date. The company says it now has commercial supply on hand to label the product and sell it to American hospitals and clinics, but the filing gives no sales, revenue or earnings figures.
FDA approved the company's ANDA for Preservative-Free Ketamine, announced October 30, 2026, ahead of the November 10, 2026 goal date.
The company says the product contains no benzethonium chloride, a preservative it describes as not GRAS-designated by the FDA.
Manufacturing is with Nephron Pharmaceuticals in West Columbia, South Carolina.
The company says it can now label the product and supply American hospitals and clinics.
Allarity Therapeutics entered a Settlement and Release Agreement with Novartis Pharma AG on October 28, 2026, resolving a liability of $4.9 million plus interest tied to a license agreement that was terminated effective January 26, 2024. Novartis agreed to accept $1.0 million as full payment, and both parties will release claims once the payment is received. Separately, the company announced on October 30, 2026 its first revenue-generating contract under its CLIA-certified laboratory services strategy, but the filing does not disclose the contract's value.
Liability owed to Novartis: $4.9 million plus interest, arising under a license agreement between Novartis and Allarity Therapeutics Europe ApS, an affiliate
Settlement payment: $1.0 million, accepted by Novartis as full payment of the liability upon receipt
Mutual releases of claims take effect upon receipt of the payment, subject to claims relating to enforcement of the agreement
October 30, 2026 press release: first revenue-generating contract under the CLIA-certified laboratory services strategy; contract value not disclosed
uniQure N.V. said the FDA accepted its Biologics License Application for ifezuntirgene inilparvovec, an investigational gene therapy for Huntington's disease, and granted Priority Review with a PDUFA target action date of May 1, 2027. The FDA also said it is tentatively planning an Advisory Committee meeting, with dates to be set later, and the company and FDA have aligned on the design of a confirmatory trial.
FDA accepted the BLA under the Accelerated Approval pathway and granted Priority Review
PDUFA target action date is May 1, 2027
FDA tentatively plans to discuss the application at an Advisory Committee meeting; the company will be notified once the date is set
Confirmatory trial design: randomized, standard-of-care, about 200 patients in a 2:1 ratio, Total Functional Capacity at 36 months as primary endpoint; U.S. patient screening planned to start by end of 2026
INOVIO announced on October 30, 2026 that the FDA granted accelerated approval for VOCERYQ, a DNA-based immunotherapy, to reduce the frequency of surgery in adults with recurrent respiratory papillomatosis (RRP). The company expects to make the product available to order and ship in about 60 days and to deploy its full field team in the first quarter of 2027, and it must submit a draft confirmatory study protocol by the end of 2026. The filing does not disclose revenue, pricing, or financial projections, so the near-term financial effect on shareholders is not quantified.
FDA granted accelerated approval on October 30, 2026 for VOCERYQ in combination with the CELLECTRA 5PSP delivery device
In the efficacy population of 26 patients, 7 (27%) had a complete response after 12 months of follow-up, based on the RRP-001 study
Order-and-ship availability expected in about 60 days; full field deployment expected in Q1 2027 with Syneos Health support
Continued approval may depend on a confirmatory study; draft protocol due by end of 2026 and final protocol expected by mid-2027
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.